Examples of Effectiveness Notice in a sentence
The Administrative Agent shall have received the Effectiveness Notice.
The summary can be a simple statement naming the drug product, listing the indication(s), and stating your reliance on the PET Safety and Effectiveness Notice, which provides the basis for the determination of safety and effectiveness required for FDA approval.
Based on the findings elucidated in the March 2000 PET Safety and Effectiveness Notice, FDA has determined that you are not required to conduct clinical trials or submit new safety and effectiveness information to obtain approval for fludeoxyglucose F 18 injection, ammonia N 13 injection, or sodium fluoride F 18 injection used in PET imaging.
Here is an example of an application summary for fludeoxyglucose F 18 injection for all three indications: In accordance with FDA’s PET Safety and Effectiveness Notice published in the Federal Register of March 10, 2000 (65 FR 12999), (Name of applicant) is submitting this new drug application, as described in section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, for fludeoxyglucose F 18 injection for the following indications: 1.
Effectiveness: Notice of other compliance with this Rule shall not invalidate the Proceedings or any fine or sanction imposed.
The information published in the PET Safety and Effectiveness Notice will form the basis for approval of 505(b)(2) NDAs for the three PET products discussed in this guidance.
Note: If FDA approves other applications for fludeoxyglucose F 18 injection submitted in accordance with the PET Safety and Effectiveness Notice, it is possible that these products could become alternative RLDs. For sodium fluoride F 18 injection, the RLD should be listed as one of the following: NDA 17-042, (18 F) as Fluoride Ion in Saline Solution, held by GE Healthcare.
Petitioners are correct that Sections 262(d)(1) and (e) only required that the Effectiveness Notice and statement of shares be sent to “holders of record,” but it does not follow that sending such correspondence to beneficial owners such as petitioners was an implicit waiver.
Again, Section 262 did not require respondent to refrain from sending the Effectiveness Notice and statement of shares to stockholders who made defective appraisals, including appraisals like petitioners that were defective for failure to comply with the “holder of record” requirement.
Because there is no approved NDA for ammonia N 13 injection at this time, the FDA can accept only NDAs for that PET drug product based on the Agency's findings in the PET Safety and Effectiveness Notice.